What are the side effects and recurrence rate of accelerated partial breast irradiation in an 81‑year‑old woman with early‑stage low‑risk breast cancer after breast‑conserving surgery?

Accelerated Partial Breast Irradiation in an 81-Year-Old: Side Effects and Recurrence Rates

For an 81-year-old woman with early-stage, low-risk breast cancer after breast-conserving surgery, accelerated partial breast irradiation (APBI) offers excellent local control with low recurrence rates (approximately 4-5% at 10 years) and favorable toxicity profiles, making it a highly appropriate treatment option that is actually preferred over whole breast irradiation in this age group.

Recurrence Rates

APBI demonstrates excellent long-term local control in appropriately selected patients:

• 10-year ipsilateral breast tumor recurrence (IBTR): 4.6% with APBI versus 3.9% with whole breast irradiation 1
• 5-year local recurrence: Consistently low across multiple randomized trials, with APBI showing non-inferiority to whole breast RT 2
• 30-year data: Long-term follow-up shows sustained local control with 12.6% recurrence rate at 30 years using interstitial brachytherapy 3

The most recent NCCN guidelines (2025) endorse APBI for patients ≥40 years meeting specific criteria, which an 81-year-old with low-risk disease would typically satisfy 4. The absolute difference in recurrence between APBI and whole breast irradiation is less than 1% at 10 years, which is clinically acceptable 1.

Side Effects Profile

Acute Toxicity (First 2 Weeks)

APBI demonstrates minimal acute toxicity:

• Grade 0-1: 95% of patients
• Grade 2: Only 5%
• No grade 3 or higher acute toxicity 5

Late Side Effects (5-Year Data)

Favorable outcomes:

• Skin toxicity: APBI shows fewer grade 2-3 late skin side effects compared to whole breast RT (6.9% vs 10.7%, p=0.020) 6
• Cosmetic results: 91-93% excellent-to-good cosmesis at 5 years, comparable to whole breast irradiation 6
• Overall late toxicity: Grade 2 or worse toxicity occurs in 23-27% of patients, similar between APBI and whole breast RT 6

Specific toxicities to monitor:

• Subcutaneous fibrosis: Grade 2-3 occurs in approximately 12% at 5 years (slightly higher than whole breast RT at 9.7%) 6
• Fat necrosis: Asymptomatic fat necrosis detected on mammography in 14.9% of patients; rarely requires intervention (2.2%) 7, 3
• Breast pain: Grade 2-3 pain in 8.4% (actually lower than whole breast RT at 11.9%) 6
• Hyperpigmentation: Mild cases in approximately 4% 7

Critical Point on Toxicity

The IRMA trial showed slightly higher soft tissue toxicity with twice-daily APBI (grade ≥3: 2.8% vs 1% with whole breast RT) 8. However, the preferred modern regimen of 30 Gy in 5 fractions every other day has the best cosmetic outcomes and likely lower toxicity 4.

Optimal Treatment Approach for This Patient

Patient Selection Criteria Met

An 81-year-old typically meets ASTRO "suitable" criteria if she has:

• Invasive ER-positive ductal carcinoma ≤2 cm
• Grade 1-2 disease
• Negative margins
• No lymphovascular invasion
• Node-negative disease 4

Recommended Dosing Regimen

Preferred: 30 Gy in 5 fractions every other day using external beam RT (IMRT/VMAT) 4

Alternative regimens:

• 40 Gy in 15 fractions (external beam)
• 34 Gy in 10 fractions twice daily (brachytherapy)
• 32 Gy in 8 fractions twice daily (brachytherapy) 4

Special Consideration for Age 81

Important context: For women ≥70 years with ER-positive, T1, node-negative disease receiving endocrine therapy, radiation can potentially be omitted entirely 2. However, the 2025 St. Gallen consensus showed >95% of experts still favor radiation therapy even in healthy older women with low-risk disease, particularly given:

• Short, convenient treatment courses now available
• Favorable life expectancy for many 81-year-olds
• Recognition that many patients don't complete years of endocrine therapy 9

APBI is particularly advantageous at age 81 because it offers:

• Completed treatment in 1-2 weeks versus 5-6 weeks
• Reduced travel burden
• Excellent efficacy with minimal toxicity
• Better quality of life compared to prolonged endocrine therapy alone 9

Common Pitfalls to Avoid

1. Don't use APBI if: Patient has BRCA1/2 mutation, lobular histology with extensive disease, positive margins, or lymphovascular invasion 4

2. Ensure pre-operative breast MRI was performed to rule out multifocal disease (done in 78.7% of appropriate cases) 7

3. Avoid twice-daily fractionation when possible; every-other-day regimens have better cosmetic outcomes 4

4. Don't assume age alone means omitting radiation: Even at 81, radiation provides meaningful local control benefit with minimal toxicity burden using modern APBI techniques